JP2024507347A5 - - Google Patents
Info
- Publication number
- JP2024507347A5 JP2024507347A5 JP2023549058A JP2023549058A JP2024507347A5 JP 2024507347 A5 JP2024507347 A5 JP 2024507347A5 JP 2023549058 A JP2023549058 A JP 2023549058A JP 2023549058 A JP2023549058 A JP 2023549058A JP 2024507347 A5 JP2024507347 A5 JP 2024507347A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- acid
- approximately
- aqueous solution
- solution composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163150510P | 2021-02-17 | 2021-02-17 | |
| US63/150,510 | 2021-02-17 | ||
| PCT/GB2022/050424 WO2022175663A1 (en) | 2021-02-17 | 2022-02-17 | Aqueous composition of an engineered protein construct comprising an fc domain |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024507347A JP2024507347A (ja) | 2024-02-19 |
| JP2024507347A5 true JP2024507347A5 (https=) | 2025-02-19 |
Family
ID=80595297
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023549058A Pending JP2024507347A (ja) | 2021-02-17 | 2022-02-17 | Ｆｃドメインを含む操作されたタンパク質コンストラクトの水性組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240166718A1 (https=) |
| EP (1) | EP4294371A1 (https=) |
| JP (1) | JP2024507347A (https=) |
| KR (1) | KR20230146579A (https=) |
| CN (1) | CN116867481A (https=) |
| AU (1) | AU2022223669A1 (https=) |
| CA (1) | CA3208945A1 (https=) |
| IL (1) | IL305010A (https=) |
| MX (1) | MX2023009614A (https=) |
| WO (1) | WO2022175663A1 (https=) |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0611901A2 (pt) | 2005-06-14 | 2012-08-28 | Amgen, Inc | composição, liofilizado, kit, e, processo para preparar uma composição |
| AU2006318583A1 (en) * | 2005-11-22 | 2007-05-31 | Wyeth | Immunoglobulin fusion protein formulations |
| GB0700523D0 (en) | 2007-01-11 | 2007-02-21 | Insense Ltd | The Stabilisation Of Proteins |
| US8420081B2 (en) | 2007-11-30 | 2013-04-16 | Abbvie, Inc. | Antibody formulations and methods of making same |
| EP2598167B1 (en) * | 2010-07-30 | 2015-04-01 | Arecor Limited | Stabilized aqueous antibody compositions |
| BR112014009146A8 (pt) | 2011-10-18 | 2017-06-20 | Coherus Biosciences Inc | formulações de etanercepte estabilizadas com aminoácidos |
| HK1209343A1 (en) | 2012-07-09 | 2016-04-01 | Coherus Biosciences, Inc. | Etanercept formulations exhibiting marked reduction in sub-visible particles |
| JP7116059B2 (ja) * | 2016-11-21 | 2022-08-09 | ジャスト－エヴォテック バイオロジックス、インコーポレイテッド | アフリベルセプト製剤及びその使用 |
| GB201703062D0 (en) * | 2017-02-24 | 2017-04-12 | Arecor Ltd | Stabilized antibody protein solutions |
| US20200069799A1 (en) * | 2018-08-28 | 2020-03-05 | Arecor Limited | Stabilized antibody protein solutions |
| US20200255496A1 (en) * | 2017-09-18 | 2020-08-13 | Amgen Inc. | Vegfr-fc fusion protein formulations |
| MX2020005170A (es) * | 2017-11-17 | 2020-10-16 | Amgen Inc | Formulaciones de proteinas de fusion vegfr-fc. |
| DK4364724T3 (da) * | 2018-05-10 | 2025-12-22 | Regeneron Pharma | Formuleringer med høj koncentration af VEGF-receptorfusionsprotein |
-
2022
- 2022-02-17 US US18/546,578 patent/US20240166718A1/en active Pending
- 2022-02-17 CN CN202280015385.1A patent/CN116867481A/zh active Pending
- 2022-02-17 KR KR1020237031179A patent/KR20230146579A/ko active Pending
- 2022-02-17 JP JP2023549058A patent/JP2024507347A/ja active Pending
- 2022-02-17 WO PCT/GB2022/050424 patent/WO2022175663A1/en not_active Ceased
- 2022-02-17 IL IL305010A patent/IL305010A/en unknown
- 2022-02-17 MX MX2023009614A patent/MX2023009614A/es unknown
- 2022-02-17 AU AU2022223669A patent/AU2022223669A1/en active Pending
- 2022-02-17 EP EP22706881.4A patent/EP4294371A1/en active Pending
- 2022-02-17 CA CA3208945A patent/CA3208945A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2600847C2 (ru) | Жидкий состав полипептидов, содержащих fc-домен иммуноглобулина | |
| JP6953433B2 (ja) | Ｖｅｇｆアンタゴニストを含む液体医薬組成物および同医薬組成物を含有する充填済みシリンジ | |
| KR102373930B1 (ko) | 정제된 재조합 폴리펩티드를 포함하는 방법 및 조성물 | |
| JP5052736B2 (ja) | タンパク質製剤 | |
| JP7374953B2 (ja) | 眼の感染症および疾患を処置するための組成物および方法 | |
| JP2024160287A (ja) | ＶＥＧＦＲ－Ｆｃ融合タンパク質製剤 | |
| KR20170087538A (ko) | 항체 제제 | |
| JP7183268B2 (ja) | 等張化剤としてリジン塩を含有するアフリベルセプト製剤及びその使用 | |
| Janciauskiene et al. | Differential detection of PAS‐positive inclusions formed by the Z, Siiyama, and Mmalton variants of α1‐antitrypsin | |
| JP2020508331A5 (https=) | ||
| JP2020508333A5 (https=) | ||
| WO2018027329A1 (en) | TGF-β ANTAGONIST CONJUGATES | |
| US20220323587A1 (en) | Dissolvable films and methods of their use | |
| CN116368224A (zh) | Ace2突变蛋白及其使用方法 | |
| JP2022544216A5 (https=) | ||
| JP2024507347A5 (https=) | ||
| KR20150130397A (ko) | 감소된 산화를 갖는 제제 | |
| WO2023164898A1 (zh) | 一种重组融合蛋白的制剂 | |
| CN115135302B (zh) | IgG:TGFβRII融合蛋白组合物 | |
| RU2022105796A (ru) | Новая композиция, содержащая антитела | |
| CN121926875A (zh) | 包含抗体的新组合物 | |
| JP2024506718A (ja) | 工学作成二量体タンパク質の安定性を高めるための水溶液組成物 | |
| JP2024506718A5 (https=) | ||
| JP2024507347A (ja) | Ｆｃドメインを含む操作されたタンパク質コンストラクトの水性組成物 | |
| JP2022519570A5 (https=) |